Dynavax Technologies Stock Price

1.36 (8.03%)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Dynavax Technologies Corp DVAX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
1.36 8.03% 18.30 06:06:16
Open Price Low Price High Price Close Price Prev Close
Bid Price Ask Price Spread News
18.30 18.35 0.05 - 1
Trades Volume Avg Volume 52 Week Range
137 10,059 - 3.58 - 20.96
Last Trade Time Type Quantity Stock Price Currency
06:06:23 60 $ 18.35 USD


Draw Mode:

Dynavax Technologies Corp Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 2.10B 114.76M 90.82M $ 46.55M $ -2.18M -0.87 -282.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -196.00k 1.50%

more financials information »

Dynavax Technologies News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical DVAX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week17.3318.3116.5417.391,779,1030.975.6%
1 Month14.4320.9614.2918.354,692,7613.8726.82%
3 Months9.4520.969.04916.284,945,1058.8593.65%
6 Months10.8420.967.0913.623,562,3887.4668.82%
1 Year4.4720.963.5810.463,971,28613.83309.4%
3 Years11.7120.961.808.302,950,6786.5956.28%
5 Years10.4024.451.809.602,422,7567.9075.96%

Dynavax Technologies Description

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of hepatitis B. Dynavax operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its HEPLISAV-B product.
Your Recent History
Dynavax Te..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211018 10:21:44